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PATIENT FACTORS AFFECTING NON-ADHERENCE TO ANTICOAGULATION
THERAPY IN AN INNER-CITY UNDERSERVED MINORITY POPULATION
Bathija S, Schumock GT, Sharp L, Gerber B, Fitzgibbon ML, Cavallari LH, Nutescu E
University of Illinois at Chicago, Chicago, IL, USA
OBJECTIVES: Minority, underserved patients, such as African Americans and His-
panics, are at increased risk of anticoagulation related complications. Evidence
shows that non-adherence has a negative influence on anticoagulation control.
Therefore, the objective of the study was to identify patient factors affecting non-
adherence with anticoagulation therapy in an inner-city, underserved minority
population.METHODS:Weconducted a cross-sectional survey of inner-cityminor-
ity patients who received care at the University of Illinois at Chicago Antithrombo-
sis Clinic. Data on socioeconomic and clinical characteristics, social support and
factors associated with modes of transport to the clinic were collected by using
survey questionnaires and reviewing medical records. Linear regression was per-
formed to identify factors that could be potentially associated with non-adherence
to anticoagulation therapy. RESULTS: A total of 243 African American (n180) and
Hispanic (n63) patients participated in the survey. The mean age was 54.30 
17.49. The majority of the patients were female (72.84%), had an education level of
high school or less (60.44%), an annual income of$15,000 (44.09%), and hadMedi-
care orMedicaid as their primary insurance (77.37%). Themean time in therapeutic
range (TTR) was 49.29  20.89% and mean non-adherence rate with anticoagula-
tion therapy was 12.62  13.81%. Linear regression analysis showed that patients
with missed appointments (p0.01), and Medicare as primary insurance (p0.03)
were more likely to be non-adherent, whereas married patients (p0.01) were less
likely to be non-adherent. CONCLUSIONS: Our findings show that patients are
more likely to be non-adherent with anticoagulation therapy when theymiss their
clinic appointments and have Medicare as their primary insurance. In addition,
marriage as a form of social support decreases the likelihood non-adherence. Fu-
ture research is needed on developing interventions that would target and rein-
force adherence behaviors, help develop self-efficacy and motivation based on
each patient’s lifestyle and social support system.
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OBJECTIVES:To report the utilization of guideline recommended statins, angioten-
sin converting enzyme inhibitors (ACEI)/angiotensin receptor blockers (ARB), and
beta-blockers (BB) for secondary prevention of coronary heart disease (CHD) in
community-dwelling Medicare beneficiaries 65 years. METHODS: Data from the
2004-2006 Medicare Current Beneficiary Survey were utilized to conduct a retro-
spective, cross-sectional study. Community-dwelling Medicare beneficiaries 65
years of age indicating a past history of CHDormyocardial infarctionwere selected.
All commercially available statins, ACEIs/ARBs, and BBs in the US, including brand,
generic and combination products, were included. Medication possession ratio
(MPR) was the proxy used for adherence, defined as 80% MPR. Descriptive statis-
tics were used with sampling weights applied for all analyses. RESULTS: The 2004,
2005 and 2006 sample sizes were 2,338,741, 2,186,251, and 2,159,661, respectively.
At least one prescription medication for statins was reported in 62.2%, 62.4% and
64.0% of beneficiaries in 2004, 2005 and 2006. Adherence in beneficiaries having at
least one prescription for a statin was 44.6% in 2004, 47.4% in 2005, and 54.5% in
2006. In 2004, 2005, and 2006, 59.1%, 55.3%, and 56.5% of beneficiaries reported at
least one prescription for anACEI/ARBwith 45.1%, 40.8%, and 57.2% of beneficiaries
with at least one prescription for an ACEI/ARB achieving80% adherence. At least
one BB prescription was reported for 57.3%, 58.4%, and 61.5% of beneficiaries in
2004, 2005, and 2006, respectively. Adherence to BBs for those beneficiaries report-
ing at least one BB prescriptionwas 35.1%, 44.5%, and 53.6% in 2004, 2005, and 2006,
respectively. The percentage of beneficiaries reporting at least one prescription for
all three medications in 2004, 2005, and 2006 were 27.5%, 26.3% and 29.4%.
CONCLUSIONS:Utilization of guideline recommended pharmacotherapies for sec-
ondary prevention of cardiovascular morbidity and mortality in this US Medicare
patient population have improved over time but remain suboptimal.
PCV78
COMPARING QUALITY OF LIFE IN A MALAYSIAN POST ACUTE CORONARY
SYNDROME POPULATION USING EQ-5D UTILITY TARIFFS FROM DIFFERENT
COUNTRIES
Azmi S1, Anchah L2, Goh A1, Fong A2
1Azmi Burhani Consulting Sdn Bhd, Petaling Jaya, Selangor, Malaysia, 2Sarawak General
Hospital Heart Centre, Kuching, Sarawak, Malaysia
OBJECTIVES: The objective of this research was to examine the differences in
quality of life (QOL) results of Malaysian post-acute coronary syndrome (post ACS)
patients calculated using utility tariffs from different countries. METHODS: This
study utilizes primary data that was collected as part of a study on the cost-effec-
tiveness of a cardiac rehabilitation programme at the Sarawak General Hospital,
Malaysia. QOL of post ACSpatientswere obtained using English andMalay versions
of the EQ-5D questionnaire that have been validated for use in the Malaysian
population. QOL scores were determined using visual analogue scale (VAS) and
calculated using a recently developed Malaysian utility tariff (derived from VAS
valuation of Malaysians) as well as existing EQ-5D tariffs from several other
countries. RESULTS: A total of 112 (female 11.6%, male 88.4%) post-ACS patients
with an average age of 56 (10.38) years answered the EQ-5D questionnaire of which
110 were usable for analysis. The patients had average left ventricular ejection
fraction (LVEF) of 50.2% on admission. Average length-of-stay in hospital and car-
diac care was 6 and 3 days respectively. Mean quality of life was 59.7 on the VAS
score and the mean predicted QOL index score using different tariffs from Malay-
sia, UK (TTO), UK (VAS), Japan (TTO), Korea (TTO), New Zealand (VAS) and US (TTO)
were 0.80, 0.72, 0.72, 0.74, 0.83, 0.68 and 0.79 respectively. CONCLUSIONS: Recent
research argues for the use of locally and culturally appropriate tariffs for different
populations. QOL scores in this sample of post ACS were different when calculated
using utility tariffs from different countries. Our findings suggest that the health
preferences of Malaysians are unique compared to those of other countries and
underscores the importance of applying country specific utility tariffs for QOL and
cost effectiveness studies.
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SURVEY OF PATIENTS WITH ATRIAL FIBRILLATION ON THE USE OF WARFARI
AND DABIGATRAN
Choi JC1, Dibonaventura MD2, Kopenhafer L2, Nelson WW1
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OBJECTIVES: To describe and compare characteristics of AF patients who have
used warfarin or the newer anticoagulant, dabigatran.METHODS: Patient surveys
were conducted via phone or internet from September to November 2011. Study
patients were 18 years old, had a diagnosis of AF, and have used either warfarin
or dabigatran. Characteristics differences were tested using chi-squared and
ANOVA for categorical and continuous variables, respectively. RESULTS: Of those
completed the survey, 204 were warfarin users and 160 were newer anticoagulant
users (NAU). Mean patient age was 65.1. Patients were predominantly male (68.7%)
and non-Hispanic white (91.2%). Nearly half (44.0%) of patients were obese and
more than half (58.0%) had a Charlson Comorbidity Index (CCI) of 1. Average
number of years with an AF diagnosis was 7. Patients were taking 6.26medications
on average. NAUweremore likely to be female (36.9% vs. 27.0%), younger (60.93 vs.
68.36 years), diagnosedmore recently (5.78 vs. 8.10 years), and hadmore education
compared to warfarin patients (all p.05). Levels of obesity (31.9% vs. 53.4%) and
CCI burden of1 (51.9% vs. 62.7%) were lower among NAU (p.05). NAUweremore
likely to use an OTC medication (38.7% vs. 12.1%) or both a prescription and OTC
medication (11.3% vs. 4.3%) to treat stomach-related symptoms (p.05). NAU were
more likely to have had a discussion about their treatment options with their
physicians (36.9% vs. 24.5%) rather than have their physician prescribing (60.6% vs.
73.5%) (p.05). NAU were significantly less likely to have considered switching
theirmedication (10.7% vs. 31.9%). Among those considered switching, cost (62.5%)
was the most common reason for NAU, and inconvenience factors for warfarin
users. CONCLUSIONS: There were some characteristic differences among AF pa-
tients. Understanding patients’ characteristics may be the first step in helping
patients to be adherent to their stroke prevention medications.
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THE DEVELOPMENT AND VALUATION OF THE SHEFFIELD PREFERENCE BASED
LEG ULCER QUESTIONNAIRE (SPVU-5D)
Palfreyman S1, Brazier J2
1Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK, 2University of Sheffield,
Sheffield, South Yorkshire, UK
OBJECTIVES: To describe the development of the Sheffield Preference-based Leg
Ulcer patient questionnaire (SPVU-5D) and value the resulting health states.
METHODS: Patient and clinician interviews (n31) were used to identify items for
inclusion. The psychometric performance of the items in the draft descriptive
system were evaluated through a postal survey of venous ulcer patients (n266).
Factor and Rasch analysis were used to guide the choice of the final items. Prefer-
enceweights for the final five item instrumentwere obtained through a time trade-
off (TTO) valuation of a representative sample of theUK general population (n160)
using regressionmodels incorporating individual level data. RESULTS:A total of 16
items were identified for inclusion. A response rate of 59% was obtained from the
postal survey (n156). Four items were excluded due to poor completion rates or
floor/ ceiling effects. Factor analysis using promax rotation showed a two factor
solution with Cronbach’s alpha coefficient of 0.91 for 0.92. Rasch analysis showed
six disordered items, which had item levels merged and the model refitted. The
final descriptive system consisted of five items with between three and five levels.
A fractional factorial design was employed to select 25 health states from the 720
defined by the final instrument. Predicted health state values were calculated and
compared to the actual values derived from the TTO valuation. The best perform-
ing model (OLS model) predicted 25 out of the 26 health states valued in the TT0 to
within 0.1, and the predicted valuewithin 0.03, 69% of the time andwithin 0.05 92%
of the time. The mean absolute error was 0.02. CONCLUSIONS: A bottom-up ap-
proach was used to design SPVU-5D. It is the only existing PRO which has utility
values assigned to the health states it describes and so can be used within eco-
nomic analysis of interventions for venous ulceration.
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IMPACT OF THE AWARENESS OF CARDIOVASCULAR DISEASE (CVD) RISK ON
THE MANAGEMENT IN HYPERTENSIVE PATIENT IN KOREA
Jeong MH1, Kim DS2, Chang HJ3, Park SW4, Hong GR5, Kim YJ6
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OBJECTIVES: According to current guidelines for the primary prevention of cardio-
vascular disease (CVD), early risk stratificationmight be critical to planning appro-
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priate management. This study was performed to explore how different methods
stratify the risk of CVD and how the awareness of CVD risk impacts its manage-
ment in hypertensive patient. METHODS: A prospective, multi-center observa-
tional studywas conducted in hypertensive patients aged 40 years in Korea. CVD
risk was assessed using the clinical algorithm (the National Cholesterol Education
Program-Adult Treatment Panel III guideline) and carotid ultrasound (CUS). Physi-
cians’ CVD risk management patterns were assessed through chart review. Pa-
tients also completed a questionnaire before and 6months after CVD risk assess-
ment to determine self-reported behavioral changes. RESULTS: Among 294 (male
65%, 618 years), 14,9, 77.8 and 7.3% patients were determined to have low, mod-
erate and high CV risk by CUS and 49.0 and 51.0% patients were low and high risk
by clinical algorithm, respectively. Among 273 patients classified as having low-to-
moderate CV risk by the clinical algorithm, approximately half of patients (51%,
138/273) were redefined as high risk by CUS. For the high-risk comparing to the
low-risk patients based on CUS, physicians set more lowered target goals for the
management of hypertension (25.8 vs. 3.6% of physicians, P0.001), LDL-choles-
terol (51.6 vs. 23.6% of physicians, P0.001) and more changed the intensities of
anti-hypertensive agent (4.9 vs. 1.2% of physicians, P0.047). Patients reported
higher rates of smoking cessation, dietary changes (reduced dietary sodium), and
increased medication compliance at 6month comparing to the baseline (P0.05,
respectively). CONCLUSIONS: This study shows that there is a significant differ-
ence in CVD risk level between clinical algorithm and CUS. However, proactive
awareness of CV risk had major effects on physician and patient behaviors in CVD
risk management.
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THE BURDEN: A NEW APPROACH TO EVALUATING VENOUS INSUFFICIENCY
Taieb C
CREES PFSA, Boulogne, France
OBJECTIVES: Evaluating the burden of a disease is a new way of measuring its
impact on the lives of sufferers, as it takes into account all the problems caused by
the illness. The ABC-V questionnaire was created and published in 2010 (Phlebol-
ogy, 2010-25:280-285).METHODS: It was administered to a population under treat-
ment with phlebotonic drugs (Ruscus aculeatus, Hespéridine méthyl chalcone,
ascorbic acid) RESULTS: Sixty-five subjects were monitored for 56 days, average
age 4716.7, gender: 60% women, with an average BMI of 24.763,95. At inclusion
and before treatment, the burden score was 32.817.6. No difference was observed
according to gender (the male score was 33.6 20.2, the female 32.315.48 p0.4),
to age (35.2  12.4 in those older than 55 vs 31.1520.2 in the younger age braced
(p0.2); There was a difference, however, in the ABC-V score dependent on sport
activity: 36.05 vs 27,68(p0.02) On days 28 and 56, the burden score was 22.613.9
and 19.613.8 respectively. The burden is therefore observed to have significantly
and statistically reduced. The quantity of effect has been measured, and the bur-
den is 27% reduced on the day 28 and 40% on day 56. Aside from averages, a
reduction in burdenwas observed in nearly 93% of subjects. For 68% of subjects the
reduction was greater than 30% by the 56th day. Greater reduction of burden was
observed in subjects who took regular exercise, vs those who did not (41% vs 38%)
and under 50 vs over 50 (47% vs 31%) The scores that improved the most were:
treatment by GP (58%), daily life (52%) and psychological impact (54%)
CONCLUSIONS: The ABC-V burden questionnaire was created and validated in
2010 (psychometric and cognitive debriefing). This study has demonstrated and
confirmed its sensitivity to change. It is available in French, English, Italian and
Spanish.
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PRELIMINARY ASSESSMENT OF THE UTILITY OF SHORT PERFORMANCE
PHYSICAL BATTERY (SPPB) AND FERRANS AND POWER’S QUALITY OF LIFE
QUESTIONNAIRE (QLI) IN ADVANCED HEART FAILURE PATIENTS
Hozayen SM1, Soliman AM2, Nelson BJ3, Hamel AV1, Eckman PM1
1Cardiovascular Division, University of Minnesota, Minneapolis, MN, USA, 2College of Pharmacy,
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OBJECTIVES: Tests of exercise capacity and quality of life (QOL) questionnaires are
used to predict outcomes in heart failure (HF) patients. The short performance
physical battery (SPPB) and Ferrans and Power’s quality of life index (QLI) are sim-
ple, free tests commonly used in geriatric and oncology patients, but data on their
use in cardiovascular diseases is limited. We sought to assess their utility in ad-
vanced HF patients.METHODS: Ten patients with advanced HF scheduled for ven-
tricular assist device implant were enrolled in this prospective, observational
study. Multiple exercise capacity tests including maximal cardiopulmonary stress
testing (CPX), 6 minute walk (6MWT), shuttle walk test (SWT), and SPPB were per-
formed. Minnesota Living With Heart Failure (MLWHF) questionnaire, SF-36 v2™,
and QLI were administered. Cardiac output was measured non-invasively by acet-
ylene rebreathing. Data were reported in meanSD. Pairwise correlations were
calculated between exercise capacity tests and QOL questionnaires. RESULTS:
Mean age was 62.18.6 years. The mean CPX duration was 5.62.9 minutes and
CPX respiratory exchange ratio (RER) was 1.20.2. The 6MWTwas 290137m, SWT
distance was 16797 m, and SPPB score was 7.7  2.6. MLWHF score was 6915,
mean SF-36 Physical Component Score (PCS) was 3010, SF-36 Mental Component
Score was 4212, and QLI was 19.24. CPX maximal cardiac output was 5.83 at
rest and 8.45.9 L/min at peak exercise. SPPB score showed a trend towards posi-
tive correlation with 6MWT (r0.6, p0.06), SF-36 PCS (r0.55, p0.096) and a
negative correlation with MLWHF score (r -0.71, p0.01). QLI was positively cor-
related with CPX RER (r0.7, p0.05), 6MWT (r0.7, p0.005), SWT distance
(r0.79, p0.03), and SF-36 PCS (r0.7, p0.01). CONCLUSIONS: SPPB and QLI cor-
related well to more laborious and technically demanding exercise capacity tests
and generic QOL indices in advanced HF patients. Additional evaluation in a
broader population of heart failure patients is needed.
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OBJECTIVES: To compare clinicians’ and patients’ views of post-stroke spasticity
(PSS) symptoms and their impact on health-related quality of life (HRQoL).
METHODS: Interviews were conducted with 13 clinicians specializing in the treat-
ment of PSS. Emergent themes from these interviews were compared with the
findings from 6 patient focus groups involving 59 patients. RESULTS: Clinicians
described altered muscle tone and spasticity as distinct manifestations of upper
motor neuron syndrome but suggested that patients do not distinguish between
the two. Clinicians perceived patients to view spasticity as muscle tightness/stiff-
ness that affects limb positioning, posture, and function, with patient values and
coping strategies influencing the degree to which PSS impacts various domains of
their lives. Existing HRQoL measures were thought to be too general and to over-
look specific consequences associated with PSS. Patients described PSS in terms of
movement difficulties, and not muscle characteristics. Specifically, patients char-
acterized PSS as an inability to direct armmovements, position the hand, and grasp
objects in the upper limbs; and, as an inability to walk, maintain balance, and
minimize the risk of falls in the lower limbs. Ten HRQoL domains were found to
fully represent the effects of PSS on individual well being: symptom impact, phys-
ical function, activities of daily living, ambulation and mobility, ambulation risk,
social function, social support, loss of role function, appearance, and adaptive
resiliency. CONCLUSIONS: While clinicians and patients generally agreed on the
functional areas affected by PSS, clinicians tended to focus on diagnostic features
of excess muscle tonicity and spasm whereas patients concentrated on the com-
plex psychosocial effects of PSS - particularly the effects of disability on their sense
of self and personal relationships. An understanding and assessment of the com-
plex ways that PSS impacts patients’ lives has clinical relevance, particularly in
terms of screening for disabling PSS and treatment decisions.
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EFFECT OF SECONDARY PREVENTIVE MEASURES ON THE HEALTH RELATED
QUALITY OF LIFE OF MYOCARDIAL INFARCTION PATIENTS
Shah J, Aparasu RR, Birtcher KK, Johnson ML
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OBJECTIVES: To assess the effect of secondary preventive measures on the Health
Related Quality of Life (HRQoL) of myocardial infarction patients. METHODS: The
Medical Expenditure Panel Survey (MEPS) data from 2004 to 2008 were used to
conduct a retrospective longitudinal study which included adults  18 years with
myocardial infarction. The lifestyle modifications considered were smoking cessa-
tion, regular exercise and weight control. Pharmacotherapy was defined as the use
of aspirin, beta-blockers, statins and ACEI/ARBs. HRQoL was determined on the
basis of the SF-12 survey instrument. Two multiple linear regression models for
physical component summary (PCS) and mental component summary (MCS)
scores were conducted. The primary independent variables included the second-
ary preventive measures. The other predisposing, enabling and need variables
were identified based on the Andersen Behavior Model. A p-value of 0.05 was
considered to be statistically significant. RESULTS: Non-smokers had a signifi-
cantly better MCS score as compared to smokers (  2.88; CI: 0.90 – 4.85; p 
0.0053). Regular exercise was significantly associated with improvement in PCS
(  3.28; CI: 1.91 – 4.64; p  0.001) and MCS ( 1.83; CI: 0.23 – 3.42; p  0.0255)
scores whereas statin use was associated with an improvement in the MCS ( 
3.31; CI: 1.80 – 4.83; p  0.001). Use of ACE/ARB, beta-blocker or aspirin and normal
BMI, however, were not associated with improvement in HRQoL. CONCLUSIONS:
Lifestyle modifications like smoking cessation and exercise combined with regular
use of statins will help to improve HRQoL in patients with myocardial infarction.
Thus these measures should be aggressively promoted among myocardial infarc-
tion patients.
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COMPARISON OF CHARLSON, ELIXHAUSER AND HRQOL-CI RISK ADJUSTMENT
MEASURES IN PREDICTING HEALTH-RELATED QUALITY OF LIFE IN HEART
FAILURE PATIENTS
Mehta HB, Aparasu RR, Johnson ML
University of Houston, Houston, TX, USA
OBJECTIVES: Comorbidities in Heart Failure (HF) patients are highly prevalent,
adversely affecting health related quality of life (HRQoL). Health related quality of
life-comorbidity index (HRQoL-CI) has been recently developed to risk adjust
HRQoL. The aim of this study was to compare the performance of HRQoL-CI with
Charlson and Elixhauser measures in predicting HRQoL in HF patients.METHODS:
The Medical Expenditure Panel Survey 2002-2008 data was used for this retrospec-
tive cross-sectional study. All adults (age 18 years) diagnosed with HF were in-
cluded in the study. International Classification of Disease, 9th Revision, Clinical
Modification and Clinical Classification Codes were used to identify HF patients, as
well as to construct different risk adjustment measures (D’hoore adaptation of
Charlson, Elixhauser and HRQoL-CI). HRQoL is documented in MEPS using short
form health survey (SF-12), with physical component score (PCS) and mental com-
A127V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 1 – A 2 5 6
